On 19 November 2014, orphan designation (EU/3/14/1356) was granted by the European Commission to Kiadis Pharma Netherlands B.V., the Netherlands, for donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment for the treatment of acute myeloid leukaemia.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment
Treatment of acute myeloid leukaemia
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
EU/3/14/1356: Public summary of opinion on orphan designation: Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment for the treatment of acute myeloid leukaemia (PDF/214.37 KB)
First published: 15/01/2015
Last updated: 28/02/2022
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: